| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 25, 2021 |
| Accession Number: | 0001213900-21-016650 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 25, 2021 |
| Accession Number: | 0001213900-21-016650 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 12, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments
EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)
EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)
EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)
Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-12) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 10/13/2023. Application Category: NDA, Application Number: 205489, Application Classification: Labeling
Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-7) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 06/25/2021. Application Category: NDA, Application Number: 205489, Application Classification: Labeling
4 - Neos Therapeutics, Inc. (0001467652) (Issuer)
4 - Neos Therapeutics, Inc. (0001467652) (Issuer)
4 - Neos Therapeutics, Inc. (0001467652) (Issuer)
SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)
SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)
SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)